证券之星消息，截至2026年1月29日收盘，可孚医疗(301087)报收于53.06元，下跌0.41%，换手率 1.35%，成交量2.63万手，成交额1.41亿元。 1月29日的资金流向数据方面，主力资金净流出392.38万元，占总成交额2.79%，游资资金净流入 1539.41万元，占总成交额10.93%，散户资金净流出1147.03万元，占总成交额8.14%。 近5日资金流向一览见下表： 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 该股主要指标及行业内排名如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 可孚医疗2025年三季报显示，前三季 ...

可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 证券之星消息，截至2026年1月27日收盘，可孚医疗(301087)报收于54.88元，下跌1.08%，换手率 1.51%，成交量2.93万手，成交额1.6亿元。 1月27日的资金流向数据方面，主力资金净流出150.77万元，占总成交额0.94%，游资资金净流出653.33 万元，占总成交额4.09%，散户资金净流入804.1万元，占总成交额5.03%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家 ...

证券之星消息，截至2026年1月26日收盘，可孚医疗(301087)报收于55.48元，下跌1.72%，换手率 1.74%，成交量3.38万手，成交额1.86亿元。 1月26日的资金流向数据方面，主力资金净流出734.45万元，占总成交额3.94%，游资资金净流入184.32 万元，占总成交额0.99%，散户资金净流入550.13万元，占总成交额2.95%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级 ...

证券之星消息，截至2026年1月23日收盘，可孚医疗(301087)报收于56.45元，上涨2.28%，换手率 1.69%，成交量3.29万手，成交额1.85亿元。 1月23日的资金流向数据方面，主力资金净流入861.71万元，占总成交额4.65%，游资资金净流入764.55 万元，占总成交额4.13%，散户资金净流出1626.25万元，占总成交额8.78%。 该股主要指标及行业内排名如下： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标 ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), indicating a slight decline in stock price and mixed capital flow on January 22, 2026 [1] - Kefu Medical reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 6.63%, with a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2] - In Q3 2025, the company achieved a single-quarter revenue of 902 million yuan, representing a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, up 38.68% year-on-year [2] Group 2 - The company has a debt ratio of 27.37% and reported investment income of 18.18 million yuan, with financial expenses recorded at -3.77 million yuan, indicating a healthy financial position [2] - The gross profit margin for Kefu Medical stands at 53.35%, showcasing strong profitability within its industry [2] - Over the past 90 days, 8 institutions have provided ratings for the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 54.56 yuan [2]

Group 1 - The core viewpoint of the article highlights the performance and financial metrics of Kefu Medical (301087) as of January 19, 2026, with a closing price of 57.73 yuan, reflecting a 1.58% increase [1] - Kefu Medical's main business involves the research, production, sales, and service of home medical devices [2] - The company reported a total revenue of 2.398 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.63% [2] - The net profit attributable to shareholders for the same period was 260 million yuan, up 3.3% year-on-year, while the net profit excluding non-recurring items was 222 million yuan, increasing by 1.46% [2] - In Q3 2025, Kefu Medical achieved a quarterly revenue of 902 million yuan, marking a significant year-on-year growth of 30.72% [2] - The company's Q3 net profit attributable to shareholders was approximately 92.83 million yuan, reflecting a 38.68% increase year-on-year, and the net profit excluding non-recurring items was about 85.80 million yuan, up 62.68% [2] - Kefu Medical's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while the gross profit margin is reported at 53.35% [2] Group 2 - Over the past 90 days, 8 institutions have provided ratings for Kefu Medical, with 7 buy ratings and 1 hold rating [2] - The average target price set by institutions for Kefu Medical over the last 90 days is 54.56 yuan [2] - On January 19, 2026, the net outflow of main funds was 317,800 yuan, accounting for 0.12% of the total transaction amount, while retail investors experienced a net outflow of 1.33 million yuan, representing 4.87% of the total transaction amount [1]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), including stock price movement and trading volume [1][2] - As of January 16, 2026, Kefu Medical's stock closed at 56.83 yuan, down 2.27%, with a turnover rate of 2.5% and a trading volume of 48,600 lots, amounting to a total transaction value of 279 million yuan [1] - The net capital outflow from major funds was 36.34 million yuan, accounting for 13.03% of the total transaction value, while retail investors saw a net inflow of 52.52 million yuan, representing 18.82% of the total transaction value [1] Group 2 - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, an increase of 6.63% year-on-year, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, reflecting a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, which is a 38.68% increase year-on-year [2] - The company's debt ratio stands at 27.37%, with an investment income of 18.18 million yuan and a financial expense of -3.77 million yuan, while maintaining a gross profit margin of 53.35% [2] Group 3 - Over the past 90 days, eight institutions have provided ratings for Kefu Medical, with seven giving a "buy" rating and one an "increase" rating, while the average target price set by institutions is 54.56 yuan [2]

Core Viewpoint - The stock of Kefu Medical (301087) has shown a slight decline, with a closing price of 59.5 yuan on January 14, 2026, down by 1.65% [1] Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, an increase of 6.63% year-on-year [2] - The net profit attributable to the parent company was 260 million yuan, up by 3.3% year-on-year [2] - The net profit after deducting non-recurring items was 222 million yuan, reflecting a year-on-year increase of 1.46% [2] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, a significant increase of 30.72% year-on-year [2] - The single-quarter net profit attributable to the parent company was approximately 92.83 million yuan, up by 38.68% year-on-year [2] - The single-quarter net profit after deducting non-recurring items was 85.80 million yuan, marking a year-on-year increase of 62.68% [2] - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan [2] - The gross profit margin is reported at 53.35% [2] Market Activity - On January 14, 2026, the net outflow of main funds was 23.53 million yuan, accounting for 3.54% of the total transaction amount [1] - Retail investors saw a net inflow of 17.96 million yuan, representing 2.7% of the total transaction amount [1] - Over the past 90 days, 8 institutions have provided ratings for Kefu Medical, with 7 buy ratings and 1 hold rating [2] - The average target price set by institutions in the last 90 days is 545.6 million yuan [2]

Group 1 - The core viewpoint of the news is that Kefu Medical (301087) has shown a positive performance in both stock price and financial results, indicating potential growth in the home medical device sector [1][2]. - As of January 12, 2026, Kefu Medical's stock closed at 59.3 yuan, up 6.69%, with a turnover rate of 6.39% and a trading volume of 124,100 hands, resulting in a transaction amount of 720 million yuan [1]. - The net inflow of main funds on January 12 was 80.17 million yuan, accounting for 11.13% of the total transaction amount, while retail investors experienced a net outflow of 54.67 million yuan, representing 7.59% of the total transaction amount [1]. Group 2 - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, reflecting a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, which is a 38.68% increase year-on-year [2]. - The company has a debt ratio of 27.37%, with investment income of 18.18 million yuan and a gross profit margin of 53.35% [2].

Core Viewpoint - The stock of Kefu Medical (301087) has shown a positive performance with a closing price of 55.58 yuan, reflecting a 2.93% increase as of January 9, 2026, with significant trading activity and mixed capital flow [1][2]. Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, representing a year-on-year increase of 6.63% [2]. - The net profit attributable to shareholders reached 260 million yuan, up 3.3% year-on-year, while the net profit excluding non-recurring items was 222 million yuan, reflecting a 1.46% increase [2]. - In Q3 2025, the company achieved a single-quarter revenue of 902 million yuan, marking a significant year-on-year growth of 30.72% [2]. - The single-quarter net profit attributable to shareholders was approximately 92.83 million yuan, up 38.68% year-on-year, and the net profit excluding non-recurring items was about 85.80 million yuan, showing a 62.68% increase [2]. - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while the gross profit margin is reported at 53.35% [2]. Market Activity - On January 9, 2026, the net outflow of main funds was 28.03 million yuan, accounting for 3.43% of the total transaction amount, while retail investors experienced a net outflow of 258.2 million yuan, representing 0.32% of the total [1]. - Conversely, speculative funds saw a net inflow of 30.62 million yuan, which is 3.74% of the total transaction amount [1]. Analyst Ratings - Over the past 90 days, eight institutions have provided ratings for Kefu Medical, with seven recommending a buy and one suggesting an increase in holdings [2]. - The average target price set by institutions in the last 90 days is 54.56 yuan [2].